Abstract
Despite extensive research, multiple sclerosis (MS) remains a disease that lacks a definitive diagnostic test to predict imminent disease relapses. Thus, patients may undergo years of unnecessary treatments. Additionally, current treatments for MS can produce dramatically different outcomes in different individuals and therefore there is a critical need to develop biomarkers for treatment efficacy and resistance. We have recently developed a novel quantitative Microwave & Magnetic (M2) proteomics method to quantitatively measure changes in proteome expression over the course of experimental autoimmune encephalomyelitis (EAE), the standard murine animal model of MS.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
